1. Rahman A, Isenberg DA. Mechanisms of disease: systemic lupus erythematosus. N Engl J Med. 2008;358:929–939.
2. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol. 2004;172:6692–6700.
3. Biesecker G, Katz S, Koffler D. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med. 1981;154:1779–1794.
4. Ortega LM, Schultz DR, Lenz O, et al. Lupus nephritis: pathologic features, epidemiology, and a guide to therapeutic decisions. Lupus. 2010;19:557–574.
5. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–530.
6. Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59:2156–2163.
7. Borchers AT, Keen CL, Shoenfeld Y, et al. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3:423–453.
8. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299–308.
9. Levinsky RJ, Cameron JS, Soothill JF. Serum immune complexes and disease activity in lupus nephritis. Lancet. 1977;1:564–567.
10. Mortensen ES, Rekvig OP. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol. 2009;20: 696–704.
11. Cruchaud A, Chenais F, Fournie GJ, et al. Immune complex deposits in systemic lupus erythematosus kidney without histological or functional alterations. Eur J Clin Invest. 1975;1975:297–309.
12. Forger F, Matthias T, Oppermann M, et al. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus. 2004;13: 36–44.
13. Amoura Z, Koutouzov S, Chabre H, et al. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000;43:76–84.
14. Bijl M, Dijstelbloem HM, Oost WW, et al. IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2002;41:62–67.
15. Villalta D, Romelli PB, Savina C, et al. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus. 2003;12:31–36.
16. Jaekel H-P, Trabandt A, Grobe N, et al. Anti-dsDNA antibody sub- types and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. Lupus. 2006;15:335–345.
17. Fenton KA, Tommeras B, Marion TN, et al. Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity. 2010;43:179–188.
18. Kohro-Kawata J, Wang P, Kawata Y, et al. Highly cationic anti- DNA antibodies in patients with lupus nephritis analyzed by two- dimensional electrophoresis and immunoblotting. Electrophoresis. 1998;19:1511–1515.
19. Mostoslavsky G, Fischel R, Yachimovich N, et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol. 2001;31: 1221–1227.
20. Zykova SN, Seredkina N, Benjaminsen J, et al. Reduced fragmentation of apoptotic chromatin is associated with nephritis in lupus-prone (NZB x NZW)F(1) mice. Arthritis Rheum. 2008;58: 813–825.
21. Lee YH, Ji JD, Song GG. Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Lupus. 2009;18(8):727–734.
22. Bergtold A, Gavhane A, D’Agati V, et al. FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol. 2006;177:7287–7295.
23. Li Y, Lee PY, Sobel ES, et al. Increased expression of FcγRI/CD64 on circulating monocytes parallels ongoing inflammation and nephritis in lupus. Arthritis Res Ther. 2009;11:R6.
24. Clynes R, Calvani N, Croker BP, et al. Modulation of immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors. Clin Exp Immunol. 2005;141:230–237.
25. Karp DR. Complement and systemic lupus erythematosus. Curr Opin Rheumatol. 2005;17:538–542.
26. Kavai M. Immune complex clearance by complement receptor type 1 in SLE. Autoimmun Rev. 2008;8:160–164.
27. Sinico RA, Ikehata M, Giammarresi G, et al. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci. 2005;1050:193–200.
28. Trendelenburg M, Lopez-Trascasa M, Potlukova E, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant. 2006;21:3115–3121.
29. Trouw LA, Groeneveld TWL, Seelen MA, et al. Anti-C1q autoantibodies desposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest. 2004;114: 679–688.
30. Boule MW, Broughton C, Mackay F, et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin- immunoglobulin G complexes. J Exp Med. 2004;199:1631–1640.
31. Kaveri SV , Mouthon L, Bayry J. Basophils and nephritis in lupus. N Engl J Med. 2010;363:1080–1082.
32. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54: 3612–3622.
33. Furie R, Looney R, Rovin B, et al, editors. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. American College of Rheumatology National Meeting 2009; Philadelphia (PA). 2009 Oct 17–21. Abstract 1149.
34. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010;70:529–540.
35. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62:222–233.
36. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62:2458–2466.
37. Roche and Biogen Idec decide to suspend ocrelizumab treatment – rheumatoid arthritis development programme on hold. Biogen Idec, 2010. 
38. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:326–337.
39. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res. 2009;61:1168–1178.
40. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62:201–210.
41. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immuno- therapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74.
42. Dingli D, Rajkumar SV . How best to use new therapies in multiple myeloma. Blood Rev. 2010;24:91–100.
43. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bort- ezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748–755.
44. Kang H-K, Michaels MA, Berner BR, et al. Very low-dose tolerance with nucleosomal peptides controls lupus and induces regulatory T cell subsets. J Immunol. 2005;174:3247–3255.
45. Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008;58:2470–2480.
46. Rand JH, Wu X-X, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-β2- glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112: 1687–1695.
47. Toong C, Wienholt L, Adelstein S. Hydroxychloroquine reduces binding of anti-double stranded DNA antibodies in vitro. Intern Med J. 2010;40(Suppl 4):17.
48. McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol. 1993;44:481–484.
49. Scaria PV , Craig JC, Shafer RH. Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: implications for stereoselective metabolism. Biopolymers. 1993;33:887–895.
50. Kwakye-Berko F, Meshnick S. Sequence preference of chloroquine binding to DNA and prevention of Z-DNA formation. Mol Biochem Paristol. 1990;39:275–278.
51. Fismen S, Mortensen ES, Rekvig OP. Nuclease deficiencies promote end-stage lupus nephritis but not nephritogenic autoimmunity in (NZBxNZW) F1 mice. Immunol Cell Biol. 2010 Jun 15.
52. Davis JC Jr, Manzi S, Yarboro C, et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus. 1999;8:68–76.
53. Mistry-Burchardi N, Schonermark U, Samtleben W. Apheresis in lupus nephritis. Ther Apher. 2001;5:161–170.
54. Yamaji K, Kim YJ, Tsuda H, et al. Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis. Ther Apher Dial. 2008;12(4):298–305.
55. Danieli MG, Palmieri C, Salvi A, et al. Synchronised therapy and high- dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher. 2002;17:72–77.
56. Sugimoto K, Yamaji K, Yang KS, et al. Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial. 2006;10:187–192.
57. Takahashi S, Wada N, Harada K. Immunoadsorbent apheresis eliminates pathogenic IgG in childhood lupus nephritis. Pediatr Int. 2007;49:817–821.
58. Pascual V , Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol. 2006;18: 676–682.
59. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum. 2006;54:3068–3070.
60. Fulmer T. Sparing steroids in lupus. SciBX. 2010;3:1–2.
61. Yao Y, Richman L, Higgs BW, et al. Neutralizaiton of interferon-α/β- inducible genes and downstream effect in a phase I trial of an anti- inteferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785–1796.